Viridian Therapeutics shares are trading higher after BTIG raised its price target on the stock from $56 to $61.
Portfolio Pulse from Benzinga Newsdesk
Viridian Therapeutics shares rose following BTIG's increase of its price target from $56 to $61.
September 26, 2024 | 5:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Viridian Therapeutics shares increased in value after BTIG raised its price target from $56 to $61, indicating positive analyst sentiment.
The increase in price target by BTIG suggests a positive outlook on Viridian Therapeutics, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100